COVID-19 and the liver: What do we know so far?

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• The COVID-19 pandemic significantly disrupted healthcare, affecting standard care for various conditions.
• Patients with pre-existing liver diseases, including hepatocellular carcinoma and transplant recipients, faced altered management due to SARS-CoV-2 transmission fears.
• COVID-19, a multisystem disease, can lead to acute liver injury or decompensation in individuals with underlying liver conditions.

Purpose of the Study:

• To review current research on COVID-19's effects on the liver.
• To discuss the management of patients with pre-existing liver disease during the pandemic.
• To address the role and considerations of SARS-CoV-2 vaccines in this patient population.

Main Methods:

• Literature review of published research on COVID-19 and liver disease.
• Analysis of the pathogenesis of liver involvement in COVID-19.
• Examination of vaccine trial data regarding liver disease patients.

Main Results:

• COVID-19 can cause liver injury through viral cytotoxicity, immune dysregulation, hypoxia, and drug toxicity.
• Patients with chronic liver disease, cirrhosis, and hepatocellular carcinoma face elevated risks of severe COVID-19 and mortality.
• Current SARS-CoV-2 vaccine trials have limited data on liver disease patients and excluded the immunocompromised.

Conclusions:

• Liver disease patients are a high-risk group for severe COVID-19 outcomes.
• Further research and specific vaccine guidance are needed for patients with pre-existing liver conditions.
• Effective management strategies are crucial for liver disease patients during the COVID-19 pandemic.